This is a multicenter, prospective cohort study. This is an observational study with no intervention. The study will consist of data collection via patient/surrogate interview and medical record review and collection of blood during the first three days of septic shock treatment . Blood samples will undergo RNA sequencing, which will be used to classify patients into sepsis phenotypes. Written informed consent from the patient or legally authorized representative (LAR) will be obtained.

Data will be collected for up to 90 days after enrollment. For patients discharged from the hospital prior to Day 28, three post-discharge assessment will be made at Day 28, Day 60, and Day 90 to ascertain vital status.

Genetic changes to human skin contribute to a wide variety of conditions and diseases that affect over 20% of the population. However, the genes and molecules that are responsible for human skin development and disease are not fully understood, preventing the development of treatment options. This proposal seeks to better understand one disease in particular, linear morphea, a form of Sclerederma that can affect the skin, muscle, and bone. This study will recruit subjects to collect and use skin tissue for the purpose of identifying the genetic causes of linear morphea.